{"id":"b6acec489e45","type":"article","url":"https://hartvaat.nl/2026/03/05/semaglutide-bij-perifeer-arterieel-vaatlijden-en-diabetes-stride-trial/","title":"Semaglutide bij perifeer arterieel vaatlijden en diabetes: STRIDE-trial","title_en":"Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["anemie-ckd","cagrisema","diabetes-en-hart","diabetes-type-1","ezetimibe","figaro-dkd","flow-trial","glp1-semaglutide-cardiovasculair","liraglutide","obesitas","orforglipron","perifeer-vaatlijden","select-trial","semaglutide","soul-trial","step-hfpef","stride-trial","summit-trial","tirzepatide"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag129","source_url":"https://doi.org/10.1093/eurheartj/ehag129","authors":["Joakim Nordanstig","Ecenur Guder Arslan","Andrei-Mircea Catarig","Kim Houlind","Bernhard Ludvik","Neda Rasouli","Harald Sourij","Sebastian Thomas","Subodh Verma","Marc P Bonaca"],"significance":7,"published":"2026-03-20","source_date":"2026-03-05","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"This EHJ article presented STRIDE trial subanalyses of semaglutide in patients with peripheral artery disease and diabetes stratified by baseline disease severity and age, informing the use of GLP-1 agonists in the PAD population.","created":"2026-07-03T10:32:36Z","updated":"2026-07-03T13:31:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Dit EHJ-artikel presenteert subanalyses van de STRIDE-trial naar semaglutide bij patiënten met perifeer arterieel vaatlijden en diabetes. De resultaten worden geanalyseerd naar ernst van het vaatlijden en leeftijd, wat bijdraagt aan de personalisatie van GLP-1-receptoragonisttherapie.","abstract_original":""}